InvestorsObserver
×
News Home

Is Johnson & Johnson (JNJ) Stock a Good Buy in Drug Manufacturers - General

Thursday, January 16, 2020 11:46 AM | InvestorsObserver Analysts

Mentioned in this article

Is Johnson & Johnson (JNJ) Stock a Good Buy in Drug Manufacturers - General

Johnson & Johnson (JNJ) is near the top in its industry group according to InvestorsObserver. JNJ gets an overall rating of 64. That means it scores higher than 64 percent of stocks. Johnson & Johnson gets a 50 rank in the Drug Manufacturers - General industry. Drug Manufacturers - General is number 3 out of 148 industries.

Click Here to get the full Stock Score Report on Johnson & Johnson (JNJ) Stock.

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Johnson & Johnson Stock Today?

Johnson & Johnson (JNJ) stock is trading at $148.22 as of 11:33 AM on Thursday, Jan 16, an increase of $1.21, or 0.82% from the previous closing price of $147.01. The stock has traded between $147.17 and $148.84 so far today. Volume today is light. So far 1,785,137 shares have traded compared to average volume of 6,169,022 shares.

To screen for more stocks like JNJ click here.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App